top of page

CRISPR for Cholesterol and Triglycerides: Everything We've Covered

17 hours ago
3 min read

Gene editing started with rare diseases affecting a few thousand people. It is now being tested against high cholesterol and high triglycerides, which affect tens of millions. This page collects everything Gene Tech Times has covered on that shift, and what it would mean if a one-time infusion could replace a daily pill.


Gene Tech Times guide cover reading CRISPR for Cholesterol and Triglycerides, everything we have covered

The two genes being targeted

Both programmes switch off a gene in the liver, permanently, with a single infusion.

  • PCSK9 controls how quickly the liver clears LDL cholesterol from the blood. Less PCSK9 means more LDL is removed. Drugs that block PCSK9 already exist and work, which makes it a well-understood target.

  • ANGPTL3 slows the breakdown of fats in the blood. People born with a non-working copy naturally have lower triglycerides and LDL cholesterol, and appear healthy, which is the strongest argument for switching it off deliberately.


The two approaches

Both use lipid nanoparticles, tiny fat bubbles that carry the editing machinery to the liver after an intravenous infusion. What they do once they arrive differs.

Base editing (Verve, now part of Eli Lilly) changes a single DNA letter without cutting both strands of the double helix. Standard CRISPR-Cas9 (CRISPR Therapeutics) cuts both strands and lets the cell's repair machinery disable the gene. The base editor makes a smaller, more precise change; the CRISPR approach has produced human results sooner.


The coverage, in order


A liver with lipid nanoparticles delivering CRISPR gene-editing machinery to DNA inside a liver cell

The argument this starts

A one-time treatment for a condition that statins already manage is a different proposition from a one-time treatment for a fatal childhood disease. Two cardiologists set out why in Should Gene Therapy Be Used for Common Diseases?, and their five questions are the clearest framing of the debate we have covered.

The short version: a pill can be stopped. An edit cannot. When millions of people are treated, a side effect that appears in one in ten thousand is no longer hypothetical. And the pricing model built for rare disease does not transfer to a condition this common.


What to watch next

  • Durability in people. The longest human data so far is around 18 months. Animal work has gone further: a Verve base editor held triglycerides down in monkeys for three years.

  • Who gets treated first. The early trials enrol people with severe inherited lipid disorders who have run out of options, not the general population. Moving beyond that group is where the hard questions start.

  • Whether lowering a number lowers risk. Cholesterol and triglyceride levels are stand-ins for what actually matters, which is heart attacks and strokes. Proving the latter takes years and very large trials.


The bottom line

Two different editing approaches have now lowered blood fats in people with a single infusion, and the effects have held for a year or more. The science is moving faster than the discussion about who should receive a permanent genetic change for a condition that pills can already control.


Keep exploring with Gene Tech Times

  • Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.

  • Go deeper: In-Depth Molecular Biology covers CRISPR, transcription, translation and DNA repair at college level, self-paced.

  • Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.

  • Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.

— T.N., Gene Tech Times

Comments


Subscribe for News

bottom of page